查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
大肠癌症市场:KOL的洞察
市场调查报告书
商品编码
1815992

大肠癌症市场:KOL的洞察

KOL Insight - Colorectal Cancer
出版日期: | 出版商: FirstWord Group | 英文 | 商品交期: 最快1-2个工作天内

价格
简介目录

本报告深入分析了不断发展的结直肠癌治疗格局，重点关注标靶治疗、免疫治疗和精准医疗的整合。报告借鉴北美和欧洲关键意见领袖的观点，探讨了当前的临床实践、分子分析的影响以及 HER2 抑制剂和 KRAS 抑制剂等新型药物的应用。

报告也回顾了有前景的在研药物、关键临床试验以及液体活检和 ctDNA 等诊断工具的进展，帮助医药专业人士深入了解转移性结直肠癌 (mCRC) 管理的新兴趋势、课题和机遇。

关键问题解答

  • 1.临床医生如何使用和看待目前的结直肠癌标靶治疗？
  • 2.预期哪一类药物将对未来转移性大肠直肠癌 (mCRC) 的处方趋势产生最大影响？
  • 3.哪些产品线最有前景？它们的潜在市场影响是什么？
  • 4.哪些临床试验有可能改变大肠直肠癌的未来治疗？
  • 5.转移性大肠直肠癌的诊断预计将如何发展？
  • 6.转移性大肠直肠癌治疗面临的主要课题和机会是什么？

主要品牌

  • ABBV-400（替利妥珠单抗/阿迪替康）
  • 阿瓦斯汀（贝伐单抗）
  • BOT/BAL（博替利单抗/巴替利单抗）
  • Braftovi（恩考拉非尼）
  • Cyramza（雷莫芦单抗）
  • Enfertu（曲妥珠单抗/德鲁替康）
  • 爱必妥（西妥昔单抗）
  • Eth Lumadenant（Arcus Biosciences）
  • Fluzakura（呋喹替尼）
  • GDC-6036（givalasib）
  • 花岗岩
  • Hetronifly/汉斯壮 (seruplimab)
  • 伊波奈昔单抗
  • Gemperli（多斯塔利单抗）
  • Keytruda（派姆单抗）
  • Clazati（阿达格拉西布）
  • Lumacras (sotorasib)
  • 穆萨斯托继
  • 肿瘤疫苗
  • Opdivo/Yervoy（纳武单抗/伊普利姆玛）
  • PRO 140（leronlimab）
  • RMC-98051/RMC-6236
  • 自由人(阿米凡他单抗)
  • Stivarga (瑞戈非尼)
  • Tuxa (图卡替尼)
  • Bactosertib
  • Vectibix (帕尼单抗)
  • XL 092 (赞札林替尼)
  • Zaltrap (齐柏西普)
  • Zihera (赞达马单抗)

研究方法：

"治疗趋势" 报告透过与全球领先的关键意见领袖 (KOL) 进行深入访谈，探讨关键疾病领域的当前和未来治疗前景。 KOL 的筛选标准非常严格，包括全球知名度、临床专业知识以及在其治疗领域的影响力。每次访谈都配有精心设计的讨论指南。这些指南由我们与 KOL 合作制定，并由行业专家进行同行评审，以确保问题全面且与当前市场动态相关。每份报告发布后，我们会持续 12 个月进行市场监测，及时提供关键意见领袖 (KOL) 的最新资讯，涵盖重要新闻事件、市场变化和市场发展。

我们的报告有何特别之处？

FirstWord Reports 是值得信赖的行业领导者，专注于製药业，为生物製药专业人士和决策者提供深入、可操作的洞察。我们深厚的行业知识使我们能够提供相关且有价值的洞察，帮助客户掌握新兴趋势，有​​效应对复杂课题。凭藉广泛的研究以及来自领先专家和关键意见领袖的独立、公正的见解，我们的报告能够提供您所需的准确性和可靠性。独家存取独家访谈和数据，以及持续的市场监测，确保您能够全面了解市场动态。我们的报告涵盖 40 多个动态疾病领域，并提供医生情报，包括 KOL 洞察和定量医生调查，以及行业专家对医疗事务、数位健康、销售和行销、市场准入和其他领域问题的看法，使您能够做出更明智的数据驱动决策，并在快速变化的行业中保持竞争力。

简介目录

This report offers an in-depth analysis of the evolving treatment landscape for colorectal cancer, focusing on targeted therapies, immunotherapies, and the integration of precision medicine. Drawing on perspectives from key opinion leaders in North America and Europe, it examines current clinical practices, the impact of molecular profiling, and the adoption of novel agents such as HER2 and KRAS inhibitors.

This report also reviews promising pipeline drugs, pivotal clinical trials, and advances in diagnostic tools like liquid biopsy and ctDNA, providing pharmaceutical professionals with a detailed understanding of emerging trends, challenges, and opportunities in mCRC management.

Key Questions Answered:

  • 1. How are current targeted therapies for colorectal cancer used and perceived by clinicians?
  • 2. Which drug classes are expected to most impact future prescribing trends in mCRC?
  • 3. What are the most promising pipeline products and their potential market impact?
  • 4. Which clinical trials could change future treatment practices in colorectal cancer?
  • 5. How is the diagnosis of metastatic colorectal cancer expected to evolve?
  • 6. What are the major challenges and opportunities in the mCRC treatment landscape?

Key Brands:

  • ABBV-400 (telisotuzumab adizutecan)
  • Avastin (bevacizumab)
  • BOT/BAL (botensilimab/balstilimab)
  • Braftovi (encorafenib)
  • Cyramza (ramucirumab)
  • Enhertu (trastuzumab deruxtecan)
  • Erbitux (cetuximab)
  • Etrumadenant (Arcus Biosciences)
  • Fruzaqla (fruquintinib)
  • GDC-6036 (divarasib)
  • GRANITE
  • Hetronifly/Hansizhuang (serplulimab)
  • Ivonescimab
  • Jemperli (dostarlimab)
  • Keytruda (pembrolizumab)
  • Krazati (adagrasib)
  • Lumakras (sotorasib)
  • Muzastotug
  • OncoVAX
  • Opdivo/Yervoy (nivolumab/iplimumab)
  • PRO 140 (leronlimab)
  • RMC-98051/RMC-6236
  • Rybrevant (amivantamab)
  • Stivarga (regorafenib)
  • Tukysa (tucatinib)
  • Vactosertib
  • Vectibix (panitumumab)
  • XL 092 (zanzalintinib)
  • Zaltrap (ziv-aflibercept)
  • Ziihera (zanidatamab)

Methodology:

Therapy Trend reports are developed through in-depth interviews with the world's foremost Key Opinion Leaders (KOLs) on the current and future treatment landscapes in major disease areas. KOLs are carefully selected based on strict screening criteria, including their global reputation, clinical expertise, and influence within their therapeutic area. Each interview is guided by a meticulously crafted discussion guide. These guides are developed in collaboration with KOLs and peer-reviewed by industry experts to ensure that the questions are comprehensive and pertinent to current market dynamics. Through continuous market monitoring over a 12-month period following the publication of each report, we provide timely updates from KOLs on key news events, market shifts, and clinical developments.

What makes our reports different?

FirstWord Reports, a trusted industry leader with an exclusive focus on the pharmaceutical sector, delivers in-depth, actionable insights for biopharma professionals and decision-makers. Our deep industry knowledge enables us to provide relevant and valuable insights that help you identify emerging trends and navigate complex challenges effectively. Backed by extensive research and independent, impartial insights from leading experts and KOLs, our reports deliver the accuracy and reliability you need. With exclusive access to interviews and data unavailable elsewhere, along with ongoing market monitoring, we give you a comprehensive view of market dynamics. Covering over 40 dynamic disease areas and providing physician intelligence, including KOL insights and quantitative physician surveys, as well as industry expert views on issues in medical affairs, digital health, sales & marketing, market access, and other areas, our reports empower you to make smarter, data-driven decisions and maintain a competitive edge in a fast-moving industry.